Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 10, 2011, Pages 1544-1551

  Kolouchova, Gabriela ^a   Brcakova, Eva ^a,c   Hirsova, Petra ^a   Sispera, Ludek ^a   Tomsik, Pavel ^a   Cermanova, Jolana ^a   Hyspler, Radek ^b   Slanarova, Martina ^b   Fuksa, Leos ^a   Lotkova, Halka ^a   Micuda, Stanislav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Bile acids; Bile duct obstruction; Cholesterol; Nuclear receptors; Pravastatin

Indexed keywords

ABC TRANSPORTER A1; ACYL COENZYME A; ALBUMIN; BILE ACID; BILIRUBIN; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; GLUCURONOSYLTRANSFERASE 1A1; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PRAVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE ACID BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CONTROLLED STUDY; DRUG MEGADOSE; GENE EXPRESSION; HOMEOSTASIS; LIVER CLEARANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

EID: 80053099585     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06748.x     Document Type: Article

References (41)

1. Trauner M, Wagner M, Fickert P, Zollner G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J. Clin. Gastroenterol. 2005; 39: S111-24.
2. Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J. Hepatol. 2009; 51: 565-80.
3. Wagner M, Halilbasic E, Marschall HU etal. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 2005; 42: 420-30.
4. Kurihara T, Akimoto M, Abe K etal. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin. Ther. 1993; 15: 890-8.
5. Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW, Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J. Hepatol. 2002; 36: 454-8.
6. Stojakovic T, Claudel T, Putz-Bankuti C etal. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2010; 209: 178-83.
7. Awad AS, Kamel R. Effect of rosuvastatin on cholestasis-induced hepatic injury in rat livers. J. Biochem. Mol. Toxicol. 2010; 24: 89-94.
8. Demirbilek S, Tas E, Gurunluoglu K etal. Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis. Pediatr. Surg. Int. 2007; 23: 155-62.
9. Dold S, Laschke MW, Lavasani S, Menger MD, Jeppsson B, Thorlacius H. Simvastatin protects against cholestasis-induced liver injury. Br. J. Pharmacol. 2009; 156: 466-74.
10. Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br. J. Pharmacol. 2009; 156: 7-27.
11. Carrella M, Fong LG, Loguercio C, Del Piano C. Enhancement of fatty acid and cholesterol synthesis accompanied by enhanced biliary but not very-low-density lipoprotein lipid secretion following sustained pravastatin blockade of hydroxymethyl glutaryl coenzyme A reductase in rat liver. Metabolism 1999; 48: 618-26.
12. Kamisako T, Ogawa H. Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the rat. J. Gastroenterol. Hepatol. 2004; 19: 879-83.
13. Takada Y, Tachizawa H, Kurihara H etal. Comparison of urinary excretion of pravastatin and temocapril in bile duct-ligated rats and Eisai hyperbilirubinemic rats (EHBR). J. Hepatobiliary Pancreat. Surg. 2004; 11: 125-8.
14. Trebicka J, Hennenberg M, Odenthal M etal. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J. Hepatol. 2010; 53: 702-12.
15. Brcakova E, Fuksa L, Cermanova J etal. Alteration of methotrexate biliary and renal elimination during extrahepatic and intrahepatic cholestasis in rats. Biol. Pharm. Bull. 2009; 32: 1978-85.
16. Tomsik P, Sispera L, Rezacova M etal. Increased melibiose/rhamnose ratio in bile of rats with acute cholestasis. J. Gastroenterol. Hepatol. 2008; 23: 1934-40.
17. Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 2007; 1773: 283-308.
18. Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y. Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J. Pharmacol. Exp. Ther. 2005; 314: 876-82.
19. Gerloff T, Stieger B, Hagenbuch B etal. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 1998; 273: 10046-50.
20. Kivisto KT, Grisk O, Hofmann U etal. Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats. Drug Metab. Dispos. 2005; 33: 1593-6.
21. Seo M, Inoue I, Ikeda M etal. Statins activate human PPARalpha promoter and increase PPARalpha mRNA expression and activation in HepG2 cells. PPAR Res. 2008; 2008: ID316306:1-11.
22. Gill S, Chow R, Brown AJ. Sterol regulators of cholesterol homeostasis and beyond: the oxysterol hypothesis revisited and revised. Prog. Lipid Res. 2008; 47: 391-404.
23. Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M, Kuroda M. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim. Biophys. Acta 1995; 1254: 7-12.
24. Joles J, Willekes-Koolschijn N, Koomans H etal. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats. Lab. Anim. 1992; 26: 269-80.
25. Kosters A, Kunne C, Looije N, Patel SB, Oude Elferink RP, Groen AK. The mechanism of ABCG5/ABCG8 in biliary cholesterol secretion in mice. J. Lipid Res. 2006; 47: 1959-66.
26. Langheim S, Yu L, von Bergmann K etal. ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile. J. Lipid Res. 2005; 46: 1732-8.
27. Wiersma H, Gatti A, Nijstad N, Kuipers F, Tietge UJ. Hepatic SR-B. I, not endothelial lipase, expression determines biliary cholesterol secretion in mice. J. Lipid Res. 2009; 50: 1571-80.
28. Geuken E, Visser DS, Leuvenink HG etal. Hepatic expression of ABC transporters G5 and G8 does not correlate with biliary cholesterol secretion in liver transplant patients. Hepatology 2005; 42: 1166-74.
29. Kosters A, Frijters RJ, Kunne C etal. Diosgenin-induced biliary cholesterol secretion in mice requires Abcg8. Hepatology 2005; 41: 141-50.
30. Kosters A, Frijters RJ, Schaap FG etal. Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. J. Hepatol. 2003; 38: 710-16.
31. Coy DJ, Wooton-Kee CR, Yan B etal. ABCG5/ABCG8-independent biliary cholesterol excretion in lactating rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2010; 299: G228-35.
32. Oude Elferink RP, Paulusma CC, Groen AK. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology 2006; 130: 908-25.
33. McIntyre N, Harry DS, Pearson AJ. The hypercholesterolaemia of obstructive jaundice. Gut 1975; 16: 379-91.
34. Campbell KM, Sabla GE, Bezerra JA. Transcriptional reprogramming in murine liver defines the physiologic consequences of biliary obstruction. J. Hepatol. 2004; 40: 14-23.
35. Kamisako T, Ogawa H. Effect of bile duct obstruction on the expression of intestinal mRNA related to cholesterol and bile acid metabolism in the rat. J. Gastroenterol. Hepatol. 2007; 22: 125-31.
36. Bravo I, Amigo L, Cohen DE etal. Role of plasma and liver cholesterol- and lipoprotein-metabolism determinants in LpX formation in the mouse. Biochim. Biophys. Acta 2007; 1770: 979-88.
37. Kojima T, Yamamoto T, Murata M, Chiba H, Kokai Y, Sawada N. Regulation of the blood-biliary barrier: interaction between gap and tight junctions in hepatocytes. Med. Electron Microsc. 2003; 36: 157-64.
38. Maly IP, Landmann L. Bile duct ligation in the rat causes upregulation of ZO-2 and decreased colocalization of claudins with ZO-1 and occludin. Histochem. Cell Biol. 2008; 129: 289-99.
39. Takakuwa Y, Kokai Y, Sasaki K etal. Bile canalicular barrier function and expression of tight-junctional molecules in rat hepatocytes during common bile duct ligation. Cell Tissue Res. 2002; 307: 181-9.
40. Zhang M, Wang XQ, Zhou YK etal. Effects of oral Lactobacillus plantarum on hepatocyte tight junction structure and function in rats with obstructive jaundice. Mol. Biol. Rep. 2010; 37: 2989-99.
41. Chen CY, Shiesh SC, Wu MC, Lin XZ. The effects of bile duct obstruction on the biliary secretion of ciprofloxacin in piglets. Am. J. Gastroenterol. 1999; 94: 2408-11.